IL2 and congenital rubella syndrome: With the rapid development of tumor immunotherapy, it has been found that CRS can be induced by a variety of immunotherapy methods, such as CAR T cell therapy (Freyer and Porter 2020), systemic IL-2 administration (Panelli et al. 2004), PD-1 inhibitors (Del Bello et al. 2021) and radiation therapy (Barker et al. 2018).